Skip to content

Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease

Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04682678
Acronym
SCM-PARK
Enrollment
6
Registered
2020-12-24
Start date
2021-03-10
Completion date
2023-07-11
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gait Disorders, Neurologic, Parkinson Disease

Brief summary

Our project is based on the fundamental hypothesis that epidural spinal cord stimulation (SCS) improves Freezing of gait (FOG) in patients with Parkinson's disease. In eight patients implantation of electrodes for SCS at the epidural thoracic level will be performed under general anaesthesia. Evaluation of gait and motor symptoms will be performed with and without stimulation, after a 3-month period for each of the stimulation conditions.This is a pilot, single centre, prospective, randomized, double blinded, cross-over study.

Detailed description

Patients will be selected in the Movement Disorders Unit, Department of Neurology, University Hospital Grenoble. A preoperative assessment with gait assessment, clinical evaluation and Non-Motor Symptoms assessment will be realized. The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.After the first post-operative month the patient will be randomized to the STIM ON condition (stimulation on, with the most effective parameters) or STIM OFF (without stimulation). The randomization will be performed in a double blinded fashion, by a neurologist working in open and not participating in the evaluations. After 3 months, the patient will be evaluated in a double blind condition, and the stimulation condition will be crossed for another period of 3 months. At the end of this second 3-month period, the patient will be again double-blind assessed. After this evaluation, the patient will enter the open phase of the study for a period of 6 months. For this last phase of the study, under STIM ON condition, an optimization of the stimulation settings will be realized, if necessary. At the end of this 6-month period of stimulation, the patient will be evaluated one last time. At all visits, clinical and gait evaluations will be carried out under chronic dopaminergic treatment. No change in antiparkinsonian treatment will be allowed during the entire study. Gait and clinical assessment will be performed at baseline and at the end of each double blinded phase and at 1-year follow-up. For the double-blind study the patient, the neurologist who performs the clinical evaluation and the expert who performs the gait test and analysis will be blind to the stimulation condition.

Interventions

PROCEDUREImplantation of electrodes for Spinal cord stimulation

The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with diagnosis of idiopathic PD 2. Aged 50-85 years 3. Having a FOG (score\> 14 at New-FOG-Questionnaire; score\> = 1 at item 2.13 of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale) despite the optimization of medical treatment 4. Drug treatment stable for at least 2 months 5. Able to give written consent.

Exclusion criteria

1. Pain syndrome (score\> = 2 at item 1.9 of the MDS-UPDRS II) 2. Psychosis 3. Severe depression 4. Severe cognitive impairment (Mini Mental Score Examination \<19) 5. Patient receiving STN DBS treatment 6. Presence of other neurological or medical pathologies interfering with walking 7. Subject in period of exclusion from another study 8. Subject under administrative or judicial supervision 9. Subject who cannot be contacted in an emergency. 10. Person with any administrative or judicial measure of deprivation of rights and liberty

Design outcomes

Primary

MeasureTime frameDescription
frequency and duration of Freezing Of Gait (FOG) episodes, objectiveMonth 6gait testing

Secondary

MeasureTime frameDescription
frequency and duration of Freezing Of Gait (FOG) episodes, subjective 2Month 12patient diary
impact of spinal cord stimulation on FOG, long term outcomeMonth 12New Freezing Of Gait-questionnaire (NFOG-Q)
impact of spinal cord stimulation on quality of life, long term outcomeMonth 12Parkinsons disease questionnaire (PDQ39)
frequency and duration of Freezing Of Gait (FOG) episodes, subjective 1Month 12New FOG-questionnaire (NFOG-Q)
impact of SCS on other non-motor symptomsMonth 12SCales for Outcomes in PArkinson's disease - Autonomic Dysfunction (SCOPA-AUT)
impact of SCS on gait during timed up and go testMonth 12timed up and go test
impact of SCS on gait during a dual cognitive-motor task testMonth 12New FOG-questionnaire (NFOG-Q)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026